Core Viewpoint - The company, Jian Shi Technology-B (09877), has received registration approval from the New Zealand Medicines and Medical Devices Safety Authority for its transcatheter aortic valve replacement system Ken-Valve and transcatheter tricuspid valve replacement system LuX-ValvePlus, which will accelerate the global commercialization of its product portfolio [1][5]. Group 1 - Jian Shi Technology-B's stock price initially rose over 8% in the morning but later adjusted to a slight increase of 0.24%, trading at HKD 8.50 with a transaction volume of HKD 3.4321 million [1][5]. - The company is actively promoting the commercialization of Ken-Valve and LuX-ValvePlus in New Zealand following their recent registration approval [1][5]. - The announcement highlights that the products have gained broad market recognition due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1][5].

公告指出，得益于产品的设计优势、已开展的注册临床试验及持续进行的疗法推广工作，Ken-Valve和 LuX-ValvePlus已获得了市场的广泛认可。随着两个重要产品取得新西兰药品和医疗器械安全局的注册 批准，公司将加快产品组合的全球商业化进程，以进一步实现本公司长期战略目标。 本文源自：智通财经网 智通财经获悉，健世科技-B(09877)涨超8%，截至发稿，涨8.49%，报9.2港元，成交额104.44万港元。 消息面上，健世科技今早发布公告称，公司的经导管主动脉瓣置换系统Ken-Valve和经血管三尖瓣置换 系统LuX-ValvePlus已于近日取得新西兰药品和医疗器械安全局的注册批准，公司正积极推动两款产品 于新西兰的商业化。 ...

公告指出，得益于产品的设计优势、已开展的注册临床试验及持续进行的疗法推广工作，Ken-Valve和 LuX-ValvePlus已获得了市场的广泛认可。随着两个重要产品取得新西兰药品和医疗器械安全局的注册 批准，公司将加快产品组合的全球商业化进程，以进一步实现本公司长期战略目标。 智通财经APP获悉，健世科技-B(09877)涨超8%，截至发稿，涨8.49%，报9.2港元，成交额104.44万港 元。 消息面上，健世科技今早发布公告称，公司的经导管主动脉瓣置换系统Ken-Valve和经血管三尖瓣置换 系统LuX-ValvePlus已于近日取得新西兰药品和医疗器械安全局的注册批准，公司正积极推动两款产品 于新西兰的商业化。 ...

公告指出，得益于产品的设计优势、已开展的注册临床试验及持续进行的疗法推广工作，Ken-Valve和 LuX-ValvePlus已获得了市场的广泛认可。随着两个重要产品取得新西兰药品和医疗器械安全局的注册 批准，公司将加快产品组合的全球商业化进程，以进一步实现本公司长期战略目标。 消息面上，健世科技今早发布公告称，公司的经导管主动脉瓣置换系统Ken-Valve和经血管三尖瓣置换 系统LuX-ValvePlus已于近日取得新西兰药品和医疗器械安全局的注册批准，公司正积极推动两款产品 于新西兰的商业化。 健世科技-B(09877)涨超8%，截至发稿，涨8.49%，报9.2港元，成交额104.44万港元。 ...

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-ValvePlus products from the New Zealand Medicines and Medical Devices Safety Authority, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - The Ken-Valve and LuX-ValvePlus systems have recently obtained registration approval in New Zealand [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages and ongoing clinical trials [1] - Continuous promotion of the therapies has contributed to the positive reception of the products [1] Group 3: Strategic Goals - The company aims to expedite the global commercialization process of its product lineup to achieve its long-term strategic objectives [1]

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-Valve Plus products in New Zealand, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - Ken-Valve and LuX-Valve Plus have been approved by the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to enhance the company's market presence and recognition due to the design advantages and ongoing clinical trials [1] Group 2: Commercialization Strategy - The company is actively promoting the commercialization of these two products in New Zealand [1] - The approval aligns with the company's long-term strategic goals for global market expansion [1]

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-Valve Plus products in New Zealand, which will accelerate its global commercialization efforts [1] Group 1: Product Approval - The Ken-Valve and LuX-Valve Plus have recently obtained registration approval from the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products in New Zealand [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1] - The successful registration of these two key products aligns with the company's long-term strategic goals [1]

自願公告 Ken-Valve和LuX-Valve Plus獲得新西蘭註冊批准 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 執行董事兼首席執行官 潘斐先生 香 港，二 零 二 六 年 二 月 二 十 六 日 本公告乃由寧波健世科技股份有限公司（「本公司」，連 同 其 附 屬 公 司，統 稱「本 集 團」）按 自 願 基 準 作 出，以 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 及 產 品 開 發 的 最 新 資 料。 於 本 公 告 日 期，本 公 司 執 行 董 事 為 潘 斐 先 生；非 執 行 董 事 為 呂 世 文 先 生、 TAN Ching ...

资金动向 根据香港联交所披露的文件，Duckling Fund,L.P.及关联方于2026年1月29日以每股均价7.9981港元增持 16万股H股股份，总价值约127.97万港元。增持后，Duckling Fund,L.P.的持股比例由5.99%升至6.04%。 业务进展情况 公司自主研发的经血管三尖瓣介入置换系统LuX-Valve Plus已获得美国FDA对其关键性注册临床试验的 无附加条件批准。这一进展被视为公司全球化战略的重要突破，为后续在美国市场的商业化奠定基础。 以上内容基于公开资料整理，不构成投资建议。 经济观察网健世科技-B(09877.HK)近期发布2025年度收入预告，预期总收入约为人民币1.05亿至1.10亿 元，其中主营业务收入约人民币9000万至9200万元，其他收入及收益约人民币1500万至1800万元。这标 志着其首个商业化年度实现可观收入，主要得益于经导管人工主动脉瓣膜系统Ken-Valve的首年商业化 推广，以及多个结构心介入产品在海外收费临床植入的进展。 ...

Group 1 - Duckling Fund.L.P. increased its stake in Kins Technology-B (09877) by purchasing 160,000 shares at a price of 7.9981 HKD per share, totaling approximately 1.2797 million HKD [1][3] - After the purchase, Duckling Fund.L.P. holds approximately 18.7503 million shares, representing a stake of 6.04% in Kins Technology-B [1][3]